FR2903311B1 - Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques - Google Patents
Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiquesInfo
- Publication number
- FR2903311B1 FR2903311B1 FR0606253A FR0606253A FR2903311B1 FR 2903311 B1 FR2903311 B1 FR 2903311B1 FR 0606253 A FR0606253 A FR 0606253A FR 0606253 A FR0606253 A FR 0606253A FR 2903311 B1 FR2903311 B1 FR 2903311B1
- Authority
- FR
- France
- Prior art keywords
- histamine
- chemotherapeutic agents
- receptor ligands
- hematopoietic progenitors
- hematological toxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004187 Histamine H4 receptors Human genes 0.000 title 1
- 108090000796 Histamine H4 receptors Proteins 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 231100000226 haematotoxicity Toxicity 0.000 title 1
- 230000003394 haemopoietic effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0606253A FR2903311B1 (fr) | 2006-07-10 | 2006-07-10 | Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques |
PCT/FR2007/001181 WO2008006974A2 (fr) | 2006-07-10 | 2007-07-10 | Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoïetiques contre la toxicite hematologique des agents chimiotherapeutiques. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0606253A FR2903311B1 (fr) | 2006-07-10 | 2006-07-10 | Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2903311A1 FR2903311A1 (fr) | 2008-01-11 |
FR2903311B1 true FR2903311B1 (fr) | 2012-06-15 |
Family
ID=37680534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0606253A Expired - Fee Related FR2903311B1 (fr) | 2006-07-10 | 2006-07-10 | Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2903311B1 (fr) |
WO (1) | WO2008006974A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150148538A1 (en) * | 2013-11-27 | 2015-05-28 | Gaetan Terrasse | Use of an h4 agonist molecule to treat acute leukemia |
FR3013595B1 (fr) * | 2013-11-27 | 2017-09-01 | Gaetan Terrasse | Utilisation d'une molecule h4 agoniste pour le traitement des leucemie aigues |
FR3048883B1 (fr) | 2016-03-18 | 2020-10-02 | Gaetan Terrasse | Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique |
EP4291073A1 (fr) | 2021-12-21 | 2023-12-20 | The Ergo Baby Carrier, Inc. | Siège sauteur réglable |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028013A1 (fr) * | 1993-05-20 | 1994-12-08 | Research Corporation Technologies, Inc. | Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique |
CA2341742A1 (fr) * | 1998-08-24 | 2000-03-02 | Maxim Pharmaceuticals, Inc. | Activation et protection de cellules t (cd4+ et cd8+) a l'aide d'un agoniste du recepteur h2 et d'autres agents activant les cellules t |
US6375944B1 (en) * | 1998-09-25 | 2002-04-23 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 |
US20040127395A1 (en) * | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
WO2005044807A2 (fr) * | 2003-09-30 | 2005-05-19 | Janssen Pharmaceutica N.V. | Composes de benzoimidazole |
US20060079510A1 (en) * | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
-
2006
- 2006-07-10 FR FR0606253A patent/FR2903311B1/fr not_active Expired - Fee Related
-
2007
- 2007-07-10 WO PCT/FR2007/001181 patent/WO2008006974A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008006974A3 (fr) | 2008-05-22 |
WO2008006974A2 (fr) | 2008-01-17 |
FR2903311A1 (fr) | 2008-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE527262T1 (de) | Neue tomaymycin derivate enhaltende zytotoxische mittel | |
EP2018863A4 (fr) | Composé hétérocyclique fusionné et utilisation | |
SE0600038L (sv) | Svarvskär och svarvverktyg | |
FR2902998B1 (fr) | Utilisation d'au moins un derive c-glycoside a titre d'agent apaisant | |
IL195492A0 (en) | Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands | |
ZA200901320B (en) | Sulfonamide derivatives as adrenerigic agonists and muscarinic antgonists | |
FR2899087B1 (fr) | Protection pour endoscope et endoscope correspondant | |
RS56044B1 (sr) | Primena kombinovanih preparata koji sadrže antimikotike | |
EP1855669A4 (fr) | Compositions liposomales pour administration parenterale d'agents | |
GB0821019D0 (en) | Nanostructures suitable for delivery of agents | |
FR2903311B1 (fr) | Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques | |
FR2905447B1 (fr) | Chapeau de protection pour recipient de fluide | |
FR2918279B1 (fr) | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan | |
FR2901816B1 (fr) | Structure d'enveloppe de protection pour un pilon | |
EP2120548A4 (fr) | Milieu hydrosoluble contenant des agents anti-microbiens | |
EP2027249A4 (fr) | Détection de plusieurs types de leucocytes | |
FR2906740B1 (fr) | Machine pour verre de lunettes | |
EP1877043A4 (fr) | Utilisation de paeonol dans l'inhibition de l'angiogenese ou dans l'amelioration de la radiosensibilisation | |
FR2907109B1 (fr) | Indicateur de position de fleche pour grue | |
FR2941864B1 (fr) | Substance active pour la protection de fgf-2 | |
FR2906173B1 (fr) | Dispositif pour l'usinage en plafond de pieces fixes | |
EP1985294A4 (fr) | Agent d'amelioration de fonction hepatique | |
FR2891810B1 (fr) | Structure de protection pour container | |
FR2900954B1 (fr) | Anti vol pour casque integral pour cycles moto cycles et assimiles | |
FR2908037B1 (fr) | Ensemble de protection pour seringue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 11 |
|
PLFP | Fee payment |
Year of fee payment: 12 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
PLFP | Fee payment |
Year of fee payment: 14 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |
|
ST | Notification of lapse |
Effective date: 20230305 |